Opioids inhibit tumor angiogenesis by suppressing VEGF signaling

Scientific Reports

Volumn 3, Issue , 2013, Pages

  Yamamizu, Kohei ^a,b,c   Furuta, Sadayoshi ^d   Hamada, Yusuke ^d   Yamashita, Akira ^d   Kuzumaki, Naoko ^e   Narita, Michiko ^d   Doi, Kento ^a,b   Katayama, Shiori ^a,b   Nagase, Hiroshi ^f   Yamashita, Jun K ^a,b   Narita, Minoru ^d  

^a KYOTO UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c NATIONAL INSTITUTE ON AGING   (United States)

^d HOSHI UNIVERSITY   (Japan)

^e KEIO UNIVERSITY   (Japan)

^f UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; KAPPA OPIATE RECEPTOR; NARCOTIC ANALGESIC AGENT; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR 2;

ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CARCINOMA, LEWIS LUNG; CELL LINE; CELL PROLIFERATION; DRUG EFFECTS; HUMAN; KNOCKOUT MOUSE; MELANOMA, EXPERIMENTAL; METABOLISM; MOUSE; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; TUMOR CELL LINE; UMBILICAL VEIN ENDOTHELIAL CELL;

ANALGESICS, OPIOID; ANGIOGENESIS INHIBITORS; ANIMALS; CARCINOMA, LEWIS LUNG; CELL LINE; CELL LINE, TUMOR; CELL PROLIFERATION; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, OPIOID, KAPPA; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 84889607799     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep03213     Document Type: Article

References (23)

1. Folkman, J. Tumor angiogenesis: Therapeutic implications. N. Engl. J. Med. 285, 1182-1186 (1971)
2. Carmeliet, P. & Baes, M. Metabolism and therapeutic angiogenesis. N. Engl. J. Med. 358, 2511-2512 (2008)
3. Bergers, G. & Benjamin, L. E. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 3, 401-410 (2003) (Pubitemid 37328844)
4. Ferrara, N. Vascular endothelial growth factor. Arterioscler Thromb. Vasc. Biol. 29, 789-791 (2009)
5. Mac Gabhann, F. & Popel, A. S. Systems biology of vascular endothelial growth factors. Microcirculation 15, 715-738 (2008)
6. Carmeliet, P. VEGF as a key mediator of angiogenesis in cancer. Oncology 69 Suppl 3, 4-10 (2005) (Pubitemid 41680947)
7. Pan, Q. et al. Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth. Cancer Cell 11, 53-67 (2007) (Pubitemid 46054517)
8. Ferrara, N.,Hillan, K. J., Gerber, H. P.&Novotny, W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov. 3, 391-400 (2004) (Pubitemid 38618122)
9. Kieffer, B. L. & Gaveriaux Ruff, C. Exploring the opioid system by gene knockout. Prog. Neurobiol. 66, 285-306 (2002) (Pubitemid 34518287)
10. Koodie, L., Ramakrishnan, S. & Roy, S. Morphine suppresses tumor angiogenesis through a HIF-1alpha/p38MAPK pathway. Am. J. Pathol. 177, 984-997 (2010)
11. Tegeder, I. et al. G protein-independent G1 cell cycle block and apoptosis with morphine in adenocarcinoma cells: involvement of p53 phosphorylation. Cancer Res. 63, 1846-1852 (2003) (Pubitemid 36460847)
12. Gupta, K. et al.Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth. Cancer Res. 62, 4491-4498 (2002) (Pubitemid 34827313)
13. Yamamizu, K. et al. The kappa opioid system regulates endothelial cell differentiation and pathfinding in vascular development. Blood 118, 775-785 (2011)
14. Olsson, A. K., Dimberg, A., Kreuger, J. & Claesson Welsh, L. VEGF receptor signalling-in control of vascular function. Nat. Rev. Mol. Cell Biol. 7, 359-371 (2006)
15. Hanahan, D. & Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86, 353-364 (1996) (Pubitemid 26272076)
16. Zabrenetzky, V., Harris, C. C., Steeg, P. S. & Roberts, D. D. Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung and breast carcinoma cell lines. Int. J. Cancer 59, 191-195 (1994) (Pubitemid 24343361)
17. Rodriguez Manzaneque, J. C. et al. Thrombospondin-1 suppresses spontaneous tumor growth and inhibits activation of matrix metalloproteinase-9 and mobilization of vascular endothelial growth factor. Proc. Natl. Acad. Sci. U S A 98, 12485-12490 (2001)
18. Nyberg, P., Xie, L. & Kalluri, R. Endogenous inhibitors of angiogenesis. Cancer Res. 65, 3967-3979 (2005) (Pubitemid 40775631)
19. Cao, Y. Endogenous angiogenesis inhibitors and their therapeutic implications. Int. J. Biochem. Cell Biol. 33, 357-369 (2001) (Pubitemid 32324004)
20. Suzuki, T. et al. Effect of repeated administration of TRK-820, a kappa-opioid receptor agonist, on tolerance to its antinociceptive and sedative actions. Brain Res. 995, 167-175 (2004) (Pubitemid 37522017)
21. Yamamizu, K., Kawasaki, K., Katayama, S., Watabe, T. & Yamashita, J. K. Enhancement of vascular progenitor potential by protein kinase A through dual induction of Flk-1 and Neuropilin-1. Blood 114, 3707-3716 (2009)
22. Yamamizu, K. et al. Convergence of Notch and beta-catenin signaling induces arterial fate in vascular progenitors. J. Cell. Biol. 189, 325-338 (2010)
23. Nishikawa, S. I., Nishikawa, S., Hirashima, M., Matsuyoshi, N. & Kodama, H. Progressive lineage analysis by cell sorting and culture identifies FLK1 1 VEcadherin 1 cells at a diverging point of endothelial and hemopoietic lineages. Development 125, 1747-1757 (1998) (Pubitemid 28256742)